Qure.ai is an artificial intelligence-led solution that enhances imaging accuracy and in turn improves health outcomes with the assistance of machine-supported tools.
“This funding round will allow us to further invest into R&D and to expand the reach of our solutions, accelerating our mission of delivering accessible and affordable healthcare to every human being,” said Prashant Warier, co-founder and CEO, Qure.ai.
Founded in 2016 by Warier and Dr Pooja Rao, and incubated by Fractal, Qure.ai is present in over 20 countries and claims to have impacted over 600,000 lives by providing fast and accurate interpretations of radiology scans within seconds, reducing time to treatment in the critical moments of care.
The company said its head-CT product is the only solution in the industry to detect every critical brain abnormality on a head CT.
“Medical imaging is one of the fields in healthcare where there is enough digitized data to turn the promise of AI into a reality. The sophistication of Qure.ai’s algorithms and predictive analytics tools, coupled with their expert team of data scientists and physicians positions them very well versus their global competitors,” said Anjana Sasidharan, Principal at Sequoia Capital India LLP.
Qure.ai’s chest X-ray automation and interpretation solution accurately interprets chest X-rays to help automatically generate chest X-ray interpretation reports, detect tuberculosis, which is one of the world’s leading infectious killers, chronic and medical emergencies like lung collapses and cardiac disorders.
“Very few companies in this category have achieved this level of both academic and real-world validation, and Qure.ai is leading across multiple use-cases and modalities,” said Ryan Collins, Managing Director, MassMutual Ventures SEA.